Published in Respiratory Therapeutics Week, October 24th, 2005
According to a study from the United States, "Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases tissue pO2 . We conducted a phase II multicenter study that assessed the efficacy and safety of efaproxiral when administered with thoracic radiation therapy (TRT), following induction chemotherapy, for treatment of locally advanced NSCLC. Fifty-one patients with locally advanced NSCLC were enrolled at 13 sites."
"Treatment comprised 2 cycles of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week